Gemphire Therapeutics (NASDAQ:GEMP) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Thursday.
Several other analysts have also issued reports on the stock. HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of Gemphire Therapeutics in a research report on Thursday, February 1st. Zacks Investment Research lowered shares of Gemphire Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 17th. Roth Capital restated a “buy” rating and set a $30.00 price target on shares of Gemphire Therapeutics in a research report on Friday, December 22nd. Piper Jaffray Companies restated an “overweight” rating and set a $22.00 price target on shares of Gemphire Therapeutics in a research report on Friday, October 27th. Finally, Canaccord Genuity restated a “buy” rating and set a $31.00 price target on shares of Gemphire Therapeutics in a research report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $23.17.
Gemphire Therapeutics (NASDAQ:GEMP) traded down $2.39 during midday trading on Thursday, reaching $6.24. 1,743,820 shares of the company’s stock traded hands, compared to its average volume of 54,231. The company has a current ratio of 4.17, a quick ratio of 4.17 and a debt-to-equity ratio of 1.00. Gemphire Therapeutics has a twelve month low of $6.16 and a twelve month high of $21.59. The stock has a market capitalization of $66.35 and a price-to-earnings ratio of -2.15.
Institutional investors have recently bought and sold shares of the company. Advisory Services Network LLC purchased a new stake in shares of Gemphire Therapeutics during the second quarter worth about $139,000. Vanguard Group Inc. boosted its holdings in shares of Gemphire Therapeutics by 137.6% during the second quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock worth $399,000 after purchasing an additional 17,892 shares during the period. Comerica Bank purchased a new stake in shares of Gemphire Therapeutics during the third quarter worth about $850,000. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Gemphire Therapeutics by 4.5% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 159,964 shares of the company’s stock worth $1,520,000 after purchasing an additional 6,900 shares during the period. Finally, Bamco Inc. NY purchased a new stake in shares of Gemphire Therapeutics during the third quarter worth about $2,709,000. Institutional investors own 32.21% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “ValuEngine Lowers Gemphire Therapeutics (GEMP) to Strong Sell” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/08/valuengine-lowers-gemphire-therapeutics-gemp-to-strong-sell.html.
About Gemphire Therapeutics
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.